Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals

Journal of Medicinal Chemistry

Volumn 52, Issue 1, 2009, Pages 10-13

  Seth, Punit P ^a   Siwkowski, Andrew ^a   Allerson, Charles R ^a   Vasquez, Guillermo ^a   Lee, Sam ^a   Prakash, Thazha P ^a   Wancewicz, Edward V ^a   Witchell, Donna ^a   Swayze, Eric E ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LOCKED NUCLEIC ACID; NUCLEOSIDE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; ANIMAL; BAGG ALBINO MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; LIVER; MALE; TOXICITY TESTING;

ANIMALS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIVER; MALE; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NUCLEIC ACID CONFORMATION; NUCLEOSIDES; OLIGONUCLEOTIDES, ANTISENSE; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; TOXICITY TESTS;

EID: 59449093219     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801294h     Document Type: Article

References (19)

1. Crooke, S. T. Antisense Drug Technology: Principles, Strategies, and Applications, 2nd ed.; CRC Press: Boca Raton, FL, 2007; p 799.
2. Stein, C. A.; Subasinghe, C.; Shinozuka, K.; Cohen, J. S. Physico- chemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1988, 16, 3209-3221.
3. Eckstein, F. Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. 2000, 10, 117-121.
4. Monia, B. P.; Lesnik, E. A.; Gonzalez, C.; Lima, W. F.; McGee, D.; Guinosso, C. J.; Kawasaki, A. M.; Cook, P. D.; Freier, S. M. Evaluation of 2′ -modified oligonucleotides containing 2′ -deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 1993, 268, 14514-14522.
5. Geary, R. S.; Yu, R. Z.; Levin, A. A. Pharmacokinetics of phospho- rothioate antisense oligodeoxynucleotides. Curr. Opin. Invest. Drugs 2001, 2, 562-573.
6. Geary, R. S.; Yu, R. Z.; Siwkowski, A.; Levin, A. A. Pharmacokinetic/ Pharmacodynamic Properties of Phosphorothioate 2′-O-(2-Methoxy- ethyl)-Modified Antisense Oligonucleotides in Animals and Man. In Antisense Drug Technology: Principles, Strategies and Applications; Crooke, S. T., Ed.; CRC Press: Boca Raton, FL, 2007.
7. Crooke, R. M.; Graham, M. J.; Lemonidis, K. M.; Whipple, C. P.; Koo, S.; Perera, R. J. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Livid Res. 2005, 46, 872-884.
8. Kastelein, J. J. P.; Wedel, M. K.; Baker, B. F.; Su, J.; Bradley, J. D.; Yu, R. Z.; Chuang, E.; Graham, M. J.; Crooke, R. M. Potent Reduction of Apolipoprotein B and LDL Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B. Circulation 2006, 114, 1729-1735.
9. Akdim, F.; El Harchaoui, K.; Stroes, E. S.; Kastelein, J. J. Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012. Future Lipidol. 2007, 2, 387-393.
10. Freier, S. M.; Altmann, K. H. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 1997, 25, 4429-4443.
11. Obika, S.; Nanbu, D.; Hari, Y.; Morio, K.-I.; In, Y.; Ishida, T.; Imanishi, T. Synthesis of 2′-0,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Lett. 1997, 38, 8735-8738.
12. Wengel, J. Synthesis of 3′-C- and 4′-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA). Acc. Chem. Res. 1999, 32, 301-310.
13. Swayze, E. E.; Siwkowski, A. M.; Wancewicz, E. V.; Migawa, M. T.; Wyrzykiewicz, T. K.; Hung, G.; Monia, B. P.; Bennett, C. F. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 2007, 35, 687-700.
14. Henry, S. P.; Kim, T.-W.; Kramer-Strickland, K.; Zanardi, T. A.; Fey, R. A.; Levin, A. A. Toxicologic Properties of 2′O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man. In Antisense Drug Technology: Principles, Strategies and Applications, 2nd ed.; Crooke, S. T., Ed.; CRC Press: Boca Raton, FL, 2007; pp 327-364.
15. Butler, M.; McKay, R. A.; Popoff, I. J.; Gaarde, W. A.; Witchell, D.; Murray, S. F.; Dean, N. M.; Bhanot, S.; Monia, B. P. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 2002, 51, 1028-1034.
16. Yu, R. Z.; Geary, R. S.; Monteith, D. K.; Matson, J.; Truong, L.; Fitchett, J.; Levin, A. A. Tissue disposition of 2'-0-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci. 2004, 93, 48-59.
17. Seth, P. P.; Siwkowski, A.; Allerson, C. R.; Vasquez, G.; Lee, S.; Prakash, T. P.; Kinberger, G.; Migawa, M. T.; Gaus, H.; Bhat, B.; Swayze, E. E. Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. Nucleic Acids Symp. Ser. (Oxford) 2008, 52, 553-554.
18. Teplova, M.; Minasov, G.; Tereshko, V.; Inamati, G. B.; Cook, P. D.; Manoharan, M.; Egli, M. Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 1999, 6, 535-539.
19. Wagner, R. W.; Matteucci, M. D.; Grant, D.; Huang, T.; Froehler, B. C. Potent and selective inhibition of gene expression by an antisense oligonucleotide. Nat. Biotechnol. 1996, 14, 840-844. JM801294H